CytomX Therapeutics (CTMX) investor relations material

Technology platform and innovation

• Probody therapeutic platform uses biologic masking to target tumor tissue while sparing normal tissue, leveraging tumor-associated proteases for selective drug activation.

• Platform enables development of masked antibodies, cytokines, T cell engagers, and ADCs, with over a decade of experience in the field.

• Recent breakthroughs in 2025 validated the approach with encouraging clinical data.

CX-2051 clinical progress and strategy

• Phase 1 data in metastatic colorectal cancer showed 28% confirmed response rate and 5.8 months progression-free survival in heavily pretreated patients.

• Drug demonstrated a favorable safety profile, with manageable GI and hematologic toxicities.

• Enrollment expanded to 100 patients across three dose levels, with a major data update expected in Q1 next year.

• Plans include moving toward registration as a monotherapy and exploring combinations with bevacizumab, aiming for use in earlier lines of therapy.

• Potential for expansion into other solid tumors, with partnerships considered for broader development.

CX-801 and pipeline development

• Early phase 1 data for CX801 in melanoma showed clean safety and compelling biomarker activation, including T cell recruitment and checkpoint gene induction.

• Combination studies with Keytruda have begun, with data expected later next year.

• Preclinical data on CX908, a dual-masked T cell engager, demonstrated activity in lung and breast cancer models, with plans for potential partnering.